American Portfolios Advisors Novavax Inc Transaction History

American Portfolios Advisors

$2.36 Trillion
Q3 2022

A detailed history of American Portfolios Advisors transactions in Novavax Inc stock. As of the latest transaction made, American Portfolios Advisors holds 848 shares of NVAX stock, worth $7,182. This represents 0.0% of its overall portfolio holdings.

Number of Shares

848

Holding current value

$7,182

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Mar 17, 2023	BUY	$18.2 - $76.12 $15,433 - $64,549	848 New	848 $15.4 Million
Q2 2022 Mar 20, 2023	SELL	$36.28 - $75.29 $7,110 - $14,756	-196 Reduced 23.11%	652 $33.5 Million
Q1 2022 Mar 21, 2023	SELL	$69.73 - $142.9 $13,667 - $28,008	-196 Reduced 23.11%	652 $48 Million
Q4 2021 Mar 21, 2023	SELL	$134.56 - $217.97 $33,909 - $54,928	-252 Reduced 29.72%	596 $85.3 Million
Q3 2021 Mar 22, 2023	SELL	$177.8 - $270.58 $42,316 - $64,398	-238 Reduced 28.07%	610 $126 Million
Q2 2021 Mar 22, 2023	SELL	$121.0 - $257.67 $79,376 - $169,031	-656 Reduced 77.36%	192 $40.8 Million
Q1 2021 Mar 22, 2023	SELL	$112.98 - $319.93 $70,273 - $198,996	-622 Reduced 73.35%	226 $41 Million
Q4 2020 Mar 22, 2023	BUY	$78.74 - $139.5 $194,487 - $344,565	2,470 Added 291.27%	3,318 $370 Million
Q3 2020 Mar 22, 2023	SELL	$79.44 - $178.51 $17,715 - $39,807	-223 Reduced 26.3%	625 $67.7 Million
Q2 2020 Mar 24, 2023	BUY	$13.86 - $83.61 $2,772 - $16,722	200 Added 27.32%	932 $77.7 Million
Q1 2020 Mar 24, 2023	SELL	$3.93 - $16.0 $455 - $1,856	-116 Reduced 13.68%	732 $9.94 Million
Q4 2019 Mar 24, 2023	SELL	$3.69 - $5.22 $2,575 - $3,643	-698 Reduced 82.31%	150 $597,000
Q2 2019 Mar 24, 2023	SELL	$4.93 - $12.2 $3,441 - $8,515	-698 Reduced 82.31%	150 $879,000

Others Institutions Holding NVAX

# of Institutions

290

Shares Held

93.4M

Call Options Held

6.95M

Put Options Held

9.4M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Account

American Portfolios Advisors Novavax Inc Transaction History